Dispersion of Siwu Decoction Powder Veterinary Grade API into drinking-water formulations is governed by the water-extractable polysaccharide fraction and the particle-size distribution of the dried extract. The material is hygroscopic and forms cohesive aggregates when ambient relative humidity exceeds 60% RH; therefore, pre-blending with hydrous lactose monohydrate at a 1:3 to 1:5 ratio is required before the API enters the final blender. A 400 L ribbon blender operated at 15–20 rpm with 60–70% working volume provides sufficient shear to break extract agglomerates without generating excessive fines. Colloidal silicon dioxide is added at 0.5–1.0 wt% as a moisture scavenger and flow aid, and sodium lauryl sulfate is incorporated at 0.5 wt% to improve rewetting when the finished powder is added to drinking water. The blend is passed through a 1.0 mm screen and then filled into aluminium foil laminate pouches. The terminal water-soluble oral powder is intended for batch-tank administration to swine and poultry after reconstitution in potable water at 20–25 °C.

Microbiological control for this powder form follows USP <61> for total aerobic microbial count and USP <62> for specified pathogens; the release specification normally sets total aerobic count at not more than 10³ CFU/g and requires absence of Salmonella in 25 g. Loss on drying is controlled by USP <731> at not more than 5.0% because excess free moisture accelerates extract caking during storage. Species-specific dosing is fixed by the approved veterinary dossier, not by this document. A process limitation is that direct addition of the unmixed API into cold water produces gel-like lumps that block nipple-drinker lines; therefore, a pre-slurry step using a 1:10 powder-water dispersion and a high-shear mixer at 1500 rpm for 5 min is required on farm before introduction into the main tank.

Direct Compression of Siwu Decoction API Without Pre-Drying Fails Above 60% Relative Humidity

Before direct compression is attempted, the API is dried in a forced-air tray dryer at 40 °C for 2 h until loss on drying reaches 4–5%. Higher temperature is not applied because darkening and marker loss occur above 70 °C. The direct compression formulation uses API at 35–50 wt%, microcrystalline cellulose PH102 at 40–55 wt%, crospovidone at 3 wt%, povidone K30 at 2–4 wt%, colloidal silicon dioxide at 0.5 wt%, and magnesium stearate at 0.5–1.0 wt%. The API and all excipients except magnesium stearate are blended in a V-blender at 20 rpm for 15 min; the lubricant is then added and blended for an additional 3 min. Magnesium stearate must not exceed 1.5 wt% because the hydrophobic film retards wetting and prolongs disintegration beyond the release limit.

Compression is carried out on a rotary tablet press with 8 mm flat-faced beveled punches at 30 rpm, with compaction force set between 10 kN and 18 kN. Target tablet hardness is 5–8 kp. At compaction force above 18 kN, capping occurs because the elastic recovery of the dried botanical extract disrupts the compact. Tablets are tested for friability by USP <1216> with a limit of not more than 1.0%, disintegration by USP <701> in purified water at 37 °C with a limit of not more than 30 min, content uniformity by USP <905> with acceptance value not more than 15, and dissolution by USP <711> using apparatus 2 at 50 rpm in 900 mL purified water. The terminal finished product is an uncoated veterinary oral tablet. If the production suite exceeds 60% RH, picking and sticking on punch faces become unavoidable, and the batch is typically rejected due to weight variation before friability testing.

What Limits Terminal Sterilization of Paeoniflorin-Rich Siwu Decoction Injectables?

The injectable route exposes the API to three simultaneous process risks: thermal degradation of the paeoniflorin marker, precipitation of high-molecular-weight polysaccharides, and endotoxin carry-over from botanical raw material. The service form is prepared as an aqueous solution buffered to pH 5.0–6.5; below 4.5, acid hydrolysis of glycosidic bonds accelerates, and above 6.8, polyphenol oxidation produces visible darkening. Terminal sterilization at 121 °C for 15 min is acceptable only when marker retention is not less than 95% and pH drift is not more than 0.2 units. If these limits are not met, the batch is sterile-filtered through a 0.45 µm PVDF prefilter and then a 0.22 µm polyethersulfone membrane under Grade A conditions in a ISO 14644-1 Grade B background. To reduce polysaccharide flocculation during storage, the bulk solution may be ultrafiltered through a 10 kDa MWCO polyethersulfone cassette before final dilution; paeoniflorin and ferulic acid permeate, while higher-molecular-weight extract components remain in the retentate.

The injectable terminal product is a sterile solution filled into Type I borosilicate glass vials and sealed with coated butyl rubber closures. Antioxidant systems used in batch development should avoid amine-based buffering species; Siwu Decoction contains phenolic acids that can form colored amine-phenol complexes. Nitrogen sparging during compounding and headspace purging before stoppering reduce oxidative browning. Published compendial data for this specific parenteral configuration is limited, so marker loading and preservative choice are fixed against the approved veterinary dossier and stability data generated under VICH GL3. If a multi-dose presentation is required, the preservative efficacy must meet USP <51>, but the selection of preservative is species-specific because benzyl alcohol and parabens have differing toxicological limits in cats, dogs, and food-producing species.

Low-moisture capsule filling of the material is carried out at 25–30% RH and 20–22 °C, rather than ambient conditions, to prevent gelatin embrittlement and tackiness. The choice of shell material is a process-critical decision: hard gelatin capsules develop crosslinking because residual reducing sugars in the dried decoction powder can react with gelatin lysine residues under warm, moist storage; therefore, hydroxypropyl methylcellulose capsules are specified for long-duration veterinary products. The powder blend for encapsulation contains API at 200 mg, lactose monohydrate at 180 mg, pregelatinized starch at 20 mg, and talc at 3 mg per capsule, giving a total fill weight of approximately 400 mg. The API is dried to loss on drying not more than 4.0% before blending, and the blend is passed through a 30-mesh screen.

A Bosch GKF series capsule filling machine is operated at 20,000–60,000 capsules/hour depending on material index; tamping pin compression is set between 20 N and 30 N to avoid plug formation and weight segregation. The filled capsules are metal-checked, dedusted, and then tested for disintegration by USP <701> using sinkers in 0.1 N HCl at 37 °C with a limit of not more than 30 min. Dissolution is tested by USP <711> apparatus 2 at 50 rpm in 900 mL 0.1 N HCl. The terminal dosage form is a hard HPMC capsule for oral administration to companion animals or calves; packaging is cold-form aluminium blister under desiccant if the product is distributed to a climate zone exceeding 65% RH mean annual humidity.

When a Feed Premix Must Pass a 5% Coefficient-of-Variation Audit

A feed premix based on Siwu Decoction Powder Veterinary Grade API is not a simple dilution; it is a carrier-bound dry mixture in which particle-size mismatch and bulk-density difference control assay uniformity. The carrier is selected from ground corn cob #20–#40, rice hulls, or calcium carbonate, with bulk density between 0.35 g/cm³ and 0.50 g/cm³. The API is incorporated at 10–20 wt% using a two-step mixing sequence: first a basal premix is produced at 1:5 API-to-carrier ratio in a 100 L ribbon mixer for 10 min; then this basal premix is let down into the full carrier in a 500 L ribbon mixer at 15 rpm for 20–30 min. Overmixing beyond 35 min can reintroduce assay variation because the denser API-rich particles migrate toward the bottom discharge, while the lighter fibrous carrier stratifies upward. Homogeneity is verified by withdrawing 10 samples at fixed discharge intervals and calculating the coefficient of variation; the acceptance limit is not more than 5% for the marker compound, typically ferulic acid or paeoniflorin by high-performance liquid chromatography using USP <621> principles.

The finished premix is packed into 25 kg or 5 kg multi-wall paper bags with an inner polyethylene liner. Regulatory controls include current feed-industry requirements under EU Regulation 2019/4 for medicated feed intermediates and 21 CFR 225 for medicated feed manufacturing where applicable. If calcium carbonate is used as a carrier, its residual moisture must remain below 8%; a wet carbonate raises the local pH and accelerates degradation of paeoniflorin during ambient storage. The terminal product is a feed premix intended for incorporation at the feed mill into complete feed using a horizontal batch mixer with a validated mixing time. Bulk-carrier mycotoxin status should be verified by the carrier supplier because aflatoxin-controlled feed grade is not automatically granted for all botanical premix applications.

Fluidised-Bed Granulation Parameters and Granule Drying Limits

In fluidised-bed processing, the controlling variable shifts from blend uniformity to droplet penetration time and the fracture strength of agglomerates. The API is first dry-blended with corn starch at 20–30 wt% and loaded into a top-spray fluidised-bed granulator. Aqueous hydroxypropyl methylcellulose at 3% w/w is sprayed at 15–30 g/min with inlet air temperature 60–70 °C, atomization air pressure 1.5–2.0 bar, and product temperature held at 35–45 °C. Product temperature above 50 °C produces brittle granules and generates dust; below 30 °C the bed becomes overwet and loses fluidization. The spray interval is paused when the bed moisture reaches the liquid saturation phase, which is detected by an increase in pressure drop across the product retainer and a shift in outlet humidity. After the binder is exhausted, the granules are dried at inlet air 60 °C until loss on drying reaches 3–5%, then passed through a 16–20 mesh oscillating granulator.

The dried granule fraction is suitable for sachet filling, capsule filling, or final repacking as an oral granule. Bulk density is typically controlled between 0.40 g/mL and 0.55 g/mL, and the Carr index is expected to be not more than 25 when measured by ASTM D6393. Particle-size distribution is checked by sieve analysis per ISO 9276-1; material retained above 2.0 mm is rejected because it will not flow uniformly through high-speed sachet form-fill-seal dosing stations. The terminal product is a moisture-protected oral granule packaged in foil sachets under ≤30% RH. If the granulation is intended for premix let-down rather than direct oral administration, the dried granules are milled again to a #20 sieve and dry-blended with carrier to achieve the same homogeneity criteria described for premix manufacture.

Stabilization of a preserved oral liquid containing the API begins with high-shear hydration in purified water at 60 °C for 30 min, followed by cooling to 25 °C before the addition of preservative. The liquid vehicle contains sucrose at 20–30% w/v, sorbitol at 5–10% w/v, sodium benzoate at 0.1%, and citric acid to adjust pH to 4.5–5.5. Xanthan gum is incorporated at 0.1–0.3% w/v to maintain the suspension; without this suspending agent, the botanical extract deposits within 24 h and forms a hard sediment that cannot be redistributed by patient-side shaking. The batch is homogenized at 3000 rpm for 10 min in a high-shear rotor-stator mixer, then filled into 100 mL or 250 mL high-density polyethylene bottles with polypropylene child-resistant closures. The terminal product is an oral solution or suspension for veterinary use, filled under nitrogen headspace to reduce oxidative darkening of phenolic components.

Preserved oral liquids are tested for antimicrobial effectiveness by USP <51>, and the preservative level is adjusted if challenge testing against Candida albicans and Aspergillus brasiliensis fails the acceptance criteria. The formulation is incompatible with uncoated aluminium cap liners because residual organic acids migrate into the headspace and corrode the metal; polyethylene terephthalate-coated liners are specified instead. If the product is distributed as a preservative-free single-dose oral solution, the liquid must be sterile-filtered through a 0.22 µm membrane and filled aseptically. The lower pH boundary is set at 4.0; below this point, acid-catalyzed cleavage of glycosidic bonds in the decoction extract reduces paeoniflorin assay and generates glucose, which itself becomes a fermentation substrate in contaminated non-sterile liquids.